iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis
Authors' conclusion
iGlarLixi achieved greater improvements in dTIR parameters versus iGlar or Lixi in insulin-naïve and insulin-experienced AP people with T2D.
Study context
- Population
- Asian Pacific people with T2D; LixiLan-O-AP: insulin-naive; LixiLan-L-CN: insulin-treated2 trials: n = 878 and n = 426 · insulin-naive 878 · insulin-treated 426
- Comparison
- iGlarLixi vs insulin glargine 100 U/mL or lixisenatide
- Primary endpoint
- Change in dTIR (derived from seven-point SMBG) from baseline to EOT
- Follow-up
- EOT
Methodological detailsLixiLan-O-AP and LixiLan-L-CN
- LixiLan-O-AP and LixiLan-L-CN
Primary result
As reported in the abstract
Change in dTIR · baseline to EOT
ETD, % (95% CI)
iGlarLixivs iGlarLixiLan-O-AP; greater with iGlarLixi
11.45(7.66%–15.24%)
iGlarLixivs LixiLixiLan-O-AP; greater with iGlarLixi
20.54(15.74%–25.33%)
iGlarLixivs iGlarLixiLan-L-CN; greater with iGlarLixi
16.59(12.09%–21.08%)
Further findings
dTIR ≥70% (LixiLan-O-AP) · EOT
dTIR improvement ≥5% (LixiLan-O-AP) · EOT
| Outcome | iGlarLixi | iGlar | Lixi |
|---|---|---|---|
| dTIR ≥70% (LixiLan-L-CN) · EOT | 71.4% | 45.4% | — not stated in the abstract |
| dTIR improvement ≥5% (LixiLan-L-CN) · EOT | 59.8% | 39.5% | — not stated in the abstract |
— not stated in the abstract
Triple target (≥70% derived time-in-range (dTIR), <4% dTBR, <25% dTAR) · end-of-treatment (EOT)
- More patients achieved the triple target with iGlarLixi vs iGlar or lixisenatide (Lixi)
Original publication
iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U / mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis. Diabetes Obes Metab. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →